Etherna attracts Series B
Etherna, a Belgian developer of immunotherapies for the treatment of cancer and infectious diseases, has secured 34 million euros in Series B funding.
Etherna, a Belgian developer of immunotherapies for the treatment of cancer and infectious diseases, has secured 34 million euros in Series B funding.
Copyright PEI Media
Not for publication, email or dissemination